Abstract

Insecticide-treated bed nets represented a cornerstone intervention in malaria vector control, contributing 
significantly to reduced transmission across endemic regions. However, widespread pyrethroid resistance in 
Anopheles mosquito populations threatened to undermine these gains, driven primarily by enhanced metabolic 
detoxification through cytochrome P450 monooxygenases and target site mutations in voltage-gated sodium 
channels. This review examined the biochemical mechanisms underlying pyrethroid resistance in Anopheles vectors 
and evaluated the efficacy of piperonyl butoxide synergist-treated bed nets as a countermeasure strategy in 
resistance management programs. A comprehensive literature review was conducted, analyzing peer-reviewed 
publications from 2010 to 2025, focusing on pyrethroid resistance mechanisms, cytochrome P450 biochemistry, 
piperonyl butoxide pharmacology, and field trial outcomes of synergist-treated nets. Pyrethroid resistance 
manifested through multiple biochemical pathways, with cytochrome P450-mediated metabolic resistance 
representing the predominant mechanism in most African Anopheles populations. Piperonyl butoxide functioned as 
a mechanism-based cytochrome P450 inhibitor, forming stable metabolic intermediate complexes that restored 
pyrethroid susceptibility in metabolically resistant mosquitoes. Field trials demonstrated that piperonyl butoxide
treated nets provide superior epidemiological protection compared to standard pyrethroid-only nets in areas with 
confirmed metabolic resistance, reducing malaria prevalence and clinical incidence. Piperonyl butoxide-treated bed 
nets represented an evidence-based tool for maintaining vector control effectiveness in pyrethroid-resistant settings, 
though sustained impact required integration within comprehensive resistance management strategies 
incorporating surveillance, rotation policies, and novel insecticide classes.